MannKind Corporation Announces Clearance Of IND For MKC1106-PP Immunotherapy In Solid Malignancies
Tue, 28 Nov 2006 08:00 AM EST
... MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that its Investigational New Drug (IND) application for MKC1106-PP Immunotherapy in Solid Malignancies, has now been cleared by the U.S. Food and Drug Administration (FDA). [click link for full article] ...
Related Topics
- Creatinine Clearance
- Creatinine
- AIDS-Related Malignancies
- Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
- Pension
- Phosgene Oxime
- Breast Lumps & Other Breast Conditions
- Nonoxynol-9
- Tacrine
- Safety (General)
- Guanfacine
- Biodefense
- Formaldehyde
- Exelon
- National Data
- Emergency Medical Services
- Community Development
- Aspirin

Not Signed In -


